Journal of diabetes and its complications最新文献

{"title":"Kidney fat by magnetic resonance spectroscopy in type 2 diabetes with chronic kidney disease.","authors":"Niels Sondergaard Heinrich, Rune Ploegstra Pedersen, Mark Bitsch Vestergaard, Ulrich Lindberg, Ulrik Bjørn Andersen, Bryan Haddock, Alessia Fornoni, Henrik Bo Wiberg Larsson, Peter Rossing, Tine Willum Hansen","doi":"10.1016/j.jdiacomp.2024.108923","DOIUrl":"https://doi.org/10.1016/j.jdiacomp.2024.108923","url":null,"abstract":"<p><strong>Background and hypothesis: </strong>The kidneys may be susceptible to ectopic fat and its lipotoxic effects, disposing them to chronic kidney disease (CKD) in type 2 diabetes (T2D). We investigated whether the kidney parenchyma fat content and kidney sinus fat volume would be higher in persons with T2D and CKD.</p><p><strong>Methods: </strong>Cross-sectional study including 29 controls, 27 persons with T2D and no CKD, and 48 persons with T2D and early CKD (urine albumin creatinine ratio (UACR) ≥ 30 mg/g). Kidney parenchyma fat content and kidney sinus fat volume were assessed using magnetic resonance spectroscopy and Dixon scans respectively.</p><p><strong>Results: </strong>In the control, T2D without CKD and T2D with CKD groups, respectively, median [1st - 3rd quartile] UACR was 5 [4 - 6], 6 [5 - 10] and 95 [43 - 278] mg/g. and mean ± standard deviation estimated glomerular filtration rate was 89 ± 11, 94 ± 11 and 77 ± 22 ml/min/1.73m². Kidney parenchyma fat content was, respectively, 1.0 [0.5-2.4], 0.7 [0.2-1.2], 1.0 [0.3-2.0] % (p = 0.26). Kidney sinus fat volume was 2.8 [1.6-7.6], 8.0 [4.7-11.3], 10.3 [5.7-14.0] ml (p < 0.01). Around 90 % of T2D participants received a sodium-glucose cotransporter-2 inhibitor or glucagon-like peptide-1 receptor agonist.</p><p><strong>Conclusions: </strong>In a setting of modern, multifactorial T2D management, kidney parenchyma fat content, evaluated with magnetic resonance spectroscopy, was similar among healthy controls and persons with T2D irrespective of CKD status. Still, kidney sinus fat volume was higher in the presence of T2D and higher still with CKD.</p>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 2","pages":"108923"},"PeriodicalIF":2.9,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of long-term glycemic burden on the incidence of diabetic foot ulcers: A retrospective study.","authors":"Zhaohui Zheng, Bin Cao, Jing Ke, Dong Zhao","doi":"10.1016/j.jdiacomp.2024.108901","DOIUrl":"https://doi.org/10.1016/j.jdiacomp.2024.108901","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to examine the association between mean cumulative glycemic burden (MCGB) and variability cumulative glycemic burden (VCGB) with diabetic foot ulcers (DFUs).</p><p><strong>Methods: </strong>Participants were followed up at least 4 times with 4 recorded glycosylated hemoglobin (HbA1c) measurements. Glycemic burden during follow-up period was defined as the trapezoidal areas enclosed by the HbA1c measurements taken during two consecutive visits and the responding time interval. MCGB was calculated by dividing sum of total trapezoidal areas by the period of follow-up. VCGB was defined as the standard deviation of the trapezoidal areas divided to the mean of trapezoidal areas. To identify the association between MCGB and VCGB with DFUs, a Cox regression analysis was conducted.</p><p><strong>Results: </strong>Among 1876 diabetic patients, 138 (7.4 %) developed foot ulcers. As MCGB increased across quartiles, DFUs incidence also rose significantly (3.2 % to 16.0 %, P < 0.001). Similarly, the prevalence of DFUs increases with increasing quartiles of mean HbA1c level (3.2 % to 16.2 %; P < 0.001). When assessing VCGB, ulcer incidence gradually increased with the quartiles increased (P = 0.040), but HbA1c variability did not follow a similar trend (P = 0.133). Multivariable Cox regression analysis indicates that compared to the first quartile, both MCGB and VCGB in the fourth quartile significantly increase the risk of DFUs (HR = 2.99 and 5.29, respectively).</p><p><strong>Conclusions: </strong>Elevated MCGB and VCGB correlate positively with DFUs. In clinical practice, lowering blood glucose levels and reducing glycemic variability are both crucial for reducing the occurrence of diabetic foot ulcers.</p>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 2","pages":"108901"},"PeriodicalIF":2.9,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142854049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Slowly progressive subtype of childhood-onset type 1 diabetes as a high-risk factor for end-stage renal disease: A cohort study in Japan","authors":"Hiroshi Yokomichi ,&nbsp;Mie Mochizuki ,&nbsp;Shigeru Suzuki ,&nbsp;Yoshiya Ito ,&nbsp;Tomoyuki Hotsubo ,&nbsp;Nobuo Matsuura","doi":"10.1016/j.jdiacomp.2024.108922","DOIUrl":"10.1016/j.jdiacomp.2024.108922","url":null,"abstract":"<div><h3>Aim</h3><div>To compare the incidence of end-stage renal disease (ESRD) between slowly progressive type 1 diabetes and acute-onset type 1 diabetes.</div></div><div><h3>Methods</h3><div>This cohort study enrolled all 521 patients with childhood-onset type 1 diabetes with the year of onset from 1959 to 1996 in Hokkaido Prefecture, Japan. We calculated the ESRD incidence rate per 100,000 person-years by sex, onset year, onset age, and type 1 diabetes subtype (slowly progressive or acute-onset). We also constructed a Kaplan–Meier curve for ESRD by these risk factors.</div></div><div><h3>Results</h3><div>The data of 391 patients were gathered, among whom 66 developed ESRD. The ESRD incidence rate per 100,000 person-years was 525 among all patients; 538 and 503 among women (<em>n</em> = 235) and men (<em>n</em> = 156); 893, 413, and 225 for onset year of 1959–1979 (<em>n</em> = 107), 1980–1989 (<em>n</em> = 201), and 1990–1996 (<em>n</em> = 83); 420 and 715 for onset before (<em>n</em> = 243) and after (<em>n</em> = 148) puberty; and 1388 and 432 for the slowly progressive (<em>n</em> = 41) and acute-onset (<em>n</em> = 350) subtypes, respectively. The Kaplan–Meier curve also indicated a significantly higher incidence of ESRD in slowly progressive than in acute-onset type 1 diabetes.</div></div><div><h3>Conclusion</h3><div>The incidence of ESRD was higher in slowly progressive than acute-onset type 1 diabetes.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 1","pages":"Article 108922"},"PeriodicalIF":2.9,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142747984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic importance of baseline and changes in serum uric acid for macro/microvascular and mortality outcomes in individuals with type 2 diabetes: The Rio de Janeiro type 2 diabetes cohort","authors":"Claudia R.L. Cardoso,&nbsp;Lucas da Silva Pereira,&nbsp;Nathalie C. Leite,&nbsp;Gil F. Salles","doi":"10.1016/j.jdiacomp.2024.108921","DOIUrl":"10.1016/j.jdiacomp.2024.108921","url":null,"abstract":"<div><h3>Aims</h3><div>To investigate the associations between baseline/changes in serum uric acid (sUA) and the risks for cardiovascular/microvascular outcomes and mortality in a type 2 diabetes cohort.</div></div><div><h3>Methods</h3><div>Baseline sUA was measured in 685 individuals, and 463 had a second sUA measurement during follow-up; sUA was analyzed as a continuous variable and categorized into sex-specific tertile subgroups and low/high levels (&gt;4.5 mg/dl women; &gt;5.5 mg/dl men). The risks associated with baseline sUA and its changes were examined by Cox analyses for all outcomes.</div></div><div><h3>Results</h3><div>Median follow up was 10.7 years, there were 173 major cardiovascular events (MACEs), 268 all-cause deaths, 127 microalbuminuria, 104 renal failure, 160 retinopathy and 178 peripheral neuropathy outcomes. Baseline sUA was predictor of all outcomes, except all-cause mortality and retinopathy. In tertile and high/low sUA analyses, the hazard ratios (HRs) varied from 1.6 (microalbuminuria development) to 2.4 (MACEs; cardiovascular mortality). There was interaction with sex for MACEs, an increased risk was observed in women (HR: 2.6), but not in men (HR: 1.2). Changes in sUA were associated with the renal failure (HR: 2.4).</div></div><div><h3>Conclusions</h3><div>In a prospective cohort, high baseline sUA was a predictor of cardiovascular, renal and peripheral neuropathy. However, sUA changes were only predictor of renal failure.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 1","pages":"Article 108921"},"PeriodicalIF":2.9,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142747985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contents/Barcode","authors":"","doi":"10.1016/S1056-8727(24)00242-3","DOIUrl":"10.1016/S1056-8727(24)00242-3","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"38 12","pages":"Article 108916"},"PeriodicalIF":2.9,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142703515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of liver fibrosis progression in cohort of type 2 diabetes mellitus patients with MASLD.","authors":"Assim A Alfadda, Adel N Alqutub, Suphia M Sherbeeni, Abdullah S Aldosary, Saleh A Alqahtani, Arthur Isnani, Rukhsana Gul, Mohammad S Khaleel, Sara M Alqasim, Abdulrahman M Almaghamsi","doi":"10.1016/j.jdiacomp.2024.108910","DOIUrl":"https://doi.org/10.1016/j.jdiacomp.2024.108910","url":null,"abstract":"<p><strong>Aim: </strong>To investigate predictors of liver fibrosis progression in patients with type 2 diabetes mellitus (T2DM) over a minimum follow-up duration of three years.</p><p><strong>Methods: </strong>Two hundred and thirty-three patients completed the follow-up period and their clinical, laboratory and liver FibroScan data are reported. Patients were categorized into progressors 42 (18.0 %) and non-progressors 191 (82.0 %) based on liver fibrosis progression. Factors influencing fibrosis progression were identified by comparing these groups.</p><p><strong>Results: </strong>Progressors showed significantly increased aspartate aminotransferase (AST) (p = 0.010), increased alkaline phosphatase (ALP) (p = 0.001) and decreased platelet count (p = 0.002). Non-progressors exhibited significant decreases in diastolic blood pressure (DBP) (p = 0.050), body mass index (BMI) (p < 0.001), waist circumference (p < 0.001), gamma-glutamyl transferase (GGT) (p < 0.001), albumin (p < 0.001), alanine aminotransferase (ALT) (p = 0.022), glycosylated haemoglobin (HbA1c) (p = 0.002) and fasting blood sugar (FBS) (p = 0.030) with increase in HDL-cholesterol (p < 0.001), creatinine (p < 0.001), bilirubin (p < 0.001), and ALP (p = 0.007). Baseline parameters predictive of liver fibrosis progression included elevated AST and reduced platelet count. Delta changes from baseline to follow-up revealed that increases in ALP, BMI, waist circumference, and reduction in platelet count were correlated with fibrosis progression. Use of GLP-1 receptor agonist was associated with reduced progression.</p><p><strong>Conclusion: </strong>In conclusion, increase in ALP and waist circumference and reduction in platelet count are predictive of liver fibrosis progression in patients with T2DM. GLP-1 receptor agonists use seems to have a promising protective effect against liver fibrosis progression.</p><p><strong>Clinicaltrials: </strong>govID:NCT05697991.</p>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 2","pages":"108910"},"PeriodicalIF":2.9,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142828737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dapagliflozin improves the dysfunction of human umbilical vein endothelial cells (HUVECs) by downregulating high glucose/high fat-induced autophagy through inhibiting SGLT-2","authors":"Lijiahui Lin ,&nbsp;Siyu Zhong ,&nbsp;Ying Zhou ,&nbsp;Jie Xia ,&nbsp;Shanshan Deng ,&nbsp;Tao Jiang ,&nbsp;Aihua Jiang ,&nbsp;Zhimei Huang ,&nbsp;Jianping Wang","doi":"10.1016/j.jdiacomp.2024.108907","DOIUrl":"10.1016/j.jdiacomp.2024.108907","url":null,"abstract":"<div><h3>Objective</h3><div>To investigate the effect of Dapagliflozin (Da) on the disorders of human umbilical vein endothelial cells (HUVECs) induced by high glucose and high fat (HG/HF).</div></div><div><h3>Methods</h3><div>Immunohistochemistry and immunofluorescence were used to detect the SGLT-2 expression in thoracic aortic tissues. After transfected with overexpressed plasmid SLC5A2, autophagy and cell functions of HUVECs were detected with the treatment of autophagy inhibitor 3-MA (5 mM). HUVECs were exposed to mannitol (MAN), glucose/palmitate (Hg/PA), and Hg/PA/Da for 24 h, and the proliferation of HUVECs was detected by CCK-8. The protein expression levels, endothelial cell functions (cell proliferation, migration, tubular formation, apoptosis, and autophagy) in endothelial cells were evaluated.</div></div><div><h3>Results</h3><div>The SGLT-2 expression was found in atherosclerotic human thoracic aorta tissues and HG/PA induced HUVECs (<em>P</em> &lt; 0.05). After the overexpression of SGLT-2 in HUVECs, the proliferation, migration and tubule formation ability of HUVECs were inhibited, and autophagy and apoptosis were increased, which were reversed by 3-MA (<em>P</em> &lt; 0.05). After the addition of Sodium-glucose co-transporters 2 inhibitor, Dapagliflozin, the proliferation of HUVECs, the tubule formation, autophagy, apoptosis and migration ability of cells inhibited by HG/PA were significantly improved (<em>P</em> &lt; 0.05). Moreover, the increased protein expression levels of autophagy and apoptosis in HG/PA induced HUVECs were also decreased by the treatment of Dapagliflozin (<em>P</em> &lt; 0.05).</div></div><div><h3>Conclusions</h3><div>Dapagliflozin can improve the dysfunction of high glucose/high fat-induced human umbilical vein endothelial cells by downregulate autophagy through inhibiting SGLT-2.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 1","pages":"Article 108907"},"PeriodicalIF":2.9,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142705549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diabetic macular edema: Variations in observations with intensive treatment optimizing glycemia","authors":"Maria S. Varughese ,&nbsp;Ananth U. Nayak","doi":"10.1016/j.jdiacomp.2024.108909","DOIUrl":"10.1016/j.jdiacomp.2024.108909","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 1","pages":"Article 108909"},"PeriodicalIF":2.9,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142681381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stepwise cardiovascular risk stratification in patients with type 2 diabetes based on coronary CT assessment","authors":"Shinichi Wada ,&nbsp;Yoshitaka Iwanaga ,&nbsp;Michikazu Nakai ,&nbsp;Teruo Noguchi ,&nbsp;Yoshihiro Miyamoto","doi":"10.1016/j.jdiacomp.2024.108908","DOIUrl":"10.1016/j.jdiacomp.2024.108908","url":null,"abstract":"<div><h3>Background</h3><div>We aimed to examine the stepwise risk stratification for predicting major adverse cardiovascular events (MACE) in patients with DM and suspected coronary artery disease (CAD).</div></div><div><h3>Method</h3><div>1187 patients with suspected CAD enrolled in a prospective cohort study were examined. The patients were evaluated step-by-step with coronary artery calcification (CAC), coronary artery stenosis (CAS), and FFR_CT analysis. Hazard ratio (HR) and 95 % confidence interval (CI) for incidence MACE were calculated by Cox Proportional Hazards model for adjustment of Framingham risk score.</div></div><div><h3>Results</h3><div>During a median follow-up of 4.0 years, MACE frequently occurred in DM patients than non-DM (15.9 % vs. 5.7 %). A lower CAC threshold with &gt;0 or &gt; 50 Agatston score was significantly associated with increased MACE in DM (HR [95 % CI], 3.62 [1.12–11.67] or 4.72 [2.11–10.55], respectively), but not in non-DM. DM patients with &gt;50 CAC, CAS, and ≤ 0.71 FFR_CT value showed the HR (95 % CI) for MACE was 9.84 (4.26–22.69) as compared with those with ≤50 CAC, whereas non-DM patients showed that it was 2.56 (1.02–6.43).</div></div><div><h3>Conclusion</h3><div>Step-by-step assessment using CAC, CAS, and FFR_CT on top of clinical risk factors was useful for more accurate cardiovascular risk stratification in patients with DM.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 1","pages":"Article 108908"},"PeriodicalIF":2.9,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142681579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the antioxidant properties of semaglutide: A comprehensive review","authors":"Habib Yaribeygi ,&nbsp;Mina Maleki ,&nbsp;Behina Forouzanmehr ,&nbsp;Prashant Kesharwani ,&nbsp;Tannaz Jamialahmadi ,&nbsp;Sercan Karav ,&nbsp;Amirhossein Sahebkar","doi":"10.1016/j.jdiacomp.2024.108906","DOIUrl":"10.1016/j.jdiacomp.2024.108906","url":null,"abstract":"<div><div>Patients with diabetes commonly experience an aberrant production of free radicals and weakened antioxidative defenses, making them highly susceptible to oxidative stress development. This, in turn, can induce and promote diabetic complications. Therefore, utilizing antidiabetic agents with antioxidative properties can offer dual benefits by addressing hyperglycemia and reducing oxidative damage. Semaglutide, a recently approved oral form of glucagon-like peptide-1 (GLP-1) analogues, has shown potent antidiabetic effects. Additionally, recent studies have suggested that it possesses antioxidative properties. However, the exact effects and the molecular pathways involved are not well understood. In this review, we present the latest findings on the antioxidative impacts of semaglutide and draw conclusions about the mechanisms involved.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"38 12","pages":"Article 108906"},"PeriodicalIF":2.9,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142643999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}